IDH1 and acute myeloid leukemia: In conjunction with the IDH inhibitor approvals, the FDA also approved a real-time PCR test to qualitatively detect the presence of five and nine specific mutations in the IDH1 and IDH2 genes, respectively, in the blood or bone marrow (BM) of patients with AML (Dash et al., 2019).